Skip to Content
Merck
  • Malignant sacrococcygeal germ cell tumors in children: a 30-year experience from a single institution.

Malignant sacrococcygeal germ cell tumors in children: a 30-year experience from a single institution.

Tumori (2013-04-04)
Münevver Büyükpamukçu, Ali Varan, Serhan Küpeli, Saniye Ekinci, Sule Yalcin, Gülsev Kale, Bilgehan Yalçin, Tezer Kutluk, Canan Akyüz
ABSTRACT

Our aim was to analyze treatment results and survival characteristics of our patients with malignant sacrococcygeal germ cell tumors. Patient files of children with malignant sacrococcygeal germ cell tumors, treated at our institution between 1979 and 2009, were searched. Patient characteristics, histopathological subtypes, extension of disease, alpha-fetoprotein (AFP) level at the time of diagnosis and relapse, extent of surgical resection, chemotherapy protocols, details of radiotherapy and survival characteristics were recorded. A total of 58 patients (M/F = 20/38) with malignant sacrococcygeal germ cell tumor was included in analysis. With a mean follow-up of 156 months (range, 26 days to 288.8 months) overall and event-free survival rates of the 58 patients were 50.9% and 43.8%, respectively. AFP status of the patients (37% in patients with <10,000 ng/ml, 68.9% in patients with ≥ 10,000 ng/ml), type of resection (total vs others), coccygeal resection, chemotherapy protocol (PEB vs others) and number of chemotherapy courses had an impact on event-free survival in univariate analysis. In multivariate analysis, AFP status had the greatest effect on prognosis. Our treatment results are worse than those reported in the literature. Elevated AFP level at the time of diagnosis had a beneficial effect on prognosis, but year of diagnosis, tumor stage, presence of metastasis, tumor size and histopathological subtype had no impact on survival in patients with malignant sacrococcygeal germ cell tumors.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Actinomycin D, from Streptomyces sp., suitable for cell culture, ≥95%
Sigma-Aldrich
Actinomycin D, from Streptomyces sp., ≥95% (HPLC)
Sigma-Aldrich
Actinomycin D, from Streptomyces sp., ~98% (HPLC)
Sigma-Aldrich
Bleomycin sulfate from Streptomyces verticillus, BioXtra, crystalline
Sigma-Aldrich
Bleomycin sulfate from Streptomyces verticillus, for fluorescence, mixture of bleomycin sulfate salts, lyophilized, powder or crystals, white to off-white
Sigma-Aldrich
Etoposide, synthetic, 95.0-105.0%, powder
Sigma-Aldrich
Bleomycin sulfate from Streptomyces verticillus, crystalline, 1.5-2.0 U/mg
Sigma-Aldrich
Bleomycin sulfate from Streptomyces verticillus, 1.5-2.0 units/mg solid, BioReagent, suitable for cell culture